ATE338114T1 - Multi-tumor abweichende wachstumsgene - Google Patents

Multi-tumor abweichende wachstumsgene

Info

Publication number
ATE338114T1
ATE338114T1 AT96904836T AT96904836T ATE338114T1 AT E338114 T1 ATE338114 T1 AT E338114T1 AT 96904836 T AT96904836 T AT 96904836T AT 96904836 T AT96904836 T AT 96904836T AT E338114 T1 ATE338114 T1 AT E338114T1
Authority
AT
Austria
Prior art keywords
gene
tumor
derivative growth
growth genes
mag
Prior art date
Application number
AT96904836T
Other languages
English (en)
Inventor
Joern Bullerdiek
De Ven Willem Jan Marie Van
Henricus Francisc Schoenmakers
Rafael Mols
Original Assignee
Vlaams Interuniv Inst Biotech
Joern Bullerdiek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8220025&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE338114(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vlaams Interuniv Inst Biotech, Joern Bullerdiek filed Critical Vlaams Interuniv Inst Biotech
Application granted granted Critical
Publication of ATE338114T1 publication Critical patent/ATE338114T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
AT96904836T 1995-02-17 1996-02-19 Multi-tumor abweichende wachstumsgene ATE338114T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95200390 1995-02-17
EP95201951A EP0727487A1 (de) 1995-02-17 1995-07-14 Multi-Tumor abweichende Wachstumsgene

Publications (1)

Publication Number Publication Date
ATE338114T1 true ATE338114T1 (de) 2006-09-15

Family

ID=8220025

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96904836T ATE338114T1 (de) 1995-02-17 1996-02-19 Multi-tumor abweichende wachstumsgene

Country Status (14)

Country Link
US (3) US6544784B1 (de)
EP (3) EP0727487A1 (de)
JP (4) JPH11500614A (de)
KR (1) KR19980702276A (de)
AT (1) ATE338114T1 (de)
AU (1) AU4879096A (de)
CA (1) CA2213237A1 (de)
CZ (1) CZ247597A3 (de)
DE (2) DE69636495T2 (de)
FI (1) FI973354A7 (de)
HU (1) HUP9800028A3 (de)
NO (1) NO973685L (de)
PL (1) PL321831A1 (de)
WO (1) WO1996025493A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548122A1 (de) * 1995-12-21 1997-06-26 Joern Prof Dr Bullerdiek Nukleinsäuresequenzen von Genen der High Mobility Group Proteine sowie Verwendungen derselben
US6323329B1 (en) 1995-12-21 2001-11-27 Jorn Bullerdiek Nucleic acid sequences of genes encoding high mobility group proteins
US6720472B2 (en) 1996-07-12 2004-04-13 University Of Medicine And Dentistry Of New Jersey HMGI proteins in cancer and obesity
US6171779B1 (en) 1996-07-12 2001-01-09 University Of Medicine & Dentistry Of New Jersey HMGI proteins in cancer
AU748743B2 (en) * 1997-05-07 2002-06-13 University Of Medicine And Dentistry Of New Jersey Hmgi proteins in tumors and obesity
EP0878552A1 (de) * 1997-05-13 1998-11-18 Erasmus Universiteit Rotterdam Molekularer Nachweis von chromosomalen Veränderungen
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
ATE417927T1 (de) 1997-07-30 2009-01-15 Univ Emory Neue knochenmineralisierungsproteine, dna, vektoren, expressionssysteme
EP1078098A1 (de) 1998-05-04 2001-02-28 Dako A/S Verfahren und sonden zur detektion chromosomaler aberrationen
US6601371B1 (en) 1998-05-05 2003-08-05 Erwin Fertig Packaging machine
IT1299583B1 (it) * 1998-05-19 2000-03-16 Vander Way Limited Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
DE19904514A1 (de) * 1999-02-04 2000-08-10 Joern Bullerdiek Mittel zur Prävention und/oder Behandlung von Leiomyomen
US7151082B2 (en) 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US20050008643A1 (en) * 2001-06-27 2005-01-13 Ora Bernard Diagnostic methods and agents
WO2003051383A2 (de) * 2001-12-19 2003-06-26 Alcedo Biotech Gmbh Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
US20030219742A1 (en) * 2002-03-29 2003-11-27 Sanjay Bhanot Antisense modulation of HMGI-C expression
US20040005601A1 (en) * 2002-04-05 2004-01-08 Adam Siddiqui-Jain Methods for targeting quadruplex DNA
EP1539154A2 (de) * 2002-08-20 2005-06-15 The Arizona Board Of Regents, On Behalf Of The University Of Arizona Verfahren zur regulierung der transkription durch targeting von quadruplex-dna
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
CA2538763C (en) 2003-09-11 2015-05-05 Critical Therapeutics, Inc. Monoclonal antibodies against hmgb1
US8415315B2 (en) 2004-05-06 2013-04-09 University Of Central Florida Research Foundation, Inc. Methods and compositions for inhibiting the proliferation of cancer cells
EP1812065A4 (de) 2004-10-22 2009-09-02 Medimmune Inc Hochaffine antikörper gegen hmgb1 und anwendungsverfahren dafür
US8129130B2 (en) 2004-10-22 2012-03-06 The Feinstein Institute For Medical Research High affinity antibodies against HMGB1 and methods of use thereof
JP2009517404A (ja) 2005-11-28 2009-04-30 メディミューン，エルエルシー Ｈｍｇｂ１および／またはｒａｇｅのアンタゴニストならびにその使用方法
TW200902063A (en) 2007-02-15 2009-01-16 Univ Kumamoto Therapeutic agent comprising antibody capable of specifically binding to human hmgb-1 as active ingredient
JP5366039B2 (ja) * 2008-03-18 2013-12-11 株式会社常光 悪性腫瘍の予想、診断のための方法および組成物
US20100297649A1 (en) * 2009-04-22 2010-11-25 Oliveira Andre M Methods and materials for detecting gene amplification
US20140248294A1 (en) 2011-10-05 2014-09-04 University Of Bremen Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases
US20180127831A1 (en) * 2015-05-21 2018-05-10 Université de Montréal Prognostic markers of acute myeloid leukemia survival

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62166897A (ja) * 1986-01-20 1987-07-23 Toyo Soda Mfg Co Ltd 核内非ヒストン蛋白質に対するモノクロ−ナル抗体
US5389526A (en) * 1989-11-02 1995-02-14 Slade; Martin B. Plasmid vectors for cellular slime moulds of the genus dictyostelium
US5756307A (en) * 1991-09-20 1998-05-26 The United States Of America As Represented By The Department Of Health And Human Services Sequence of human dopamine transporter cDNA
US6171779B1 (en) * 1996-07-12 2001-01-09 University Of Medicine & Dentistry Of New Jersey HMGI proteins in cancer

Also Published As

Publication number Publication date
HUP9800028A2 (hu) 1998-04-28
JPH11500614A (ja) 1999-01-19
NO973685L (no) 1997-10-17
JP2008099698A (ja) 2008-05-01
FI973354L (fi) 1997-10-16
EP1762619B1 (de) 2013-06-26
CZ247597A3 (cs) 1998-07-15
DE69636495T2 (de) 2007-05-24
AU4879096A (en) 1996-09-04
FI973354A0 (fi) 1997-08-15
JP2009254378A (ja) 2009-11-05
NO973685D0 (no) 1997-08-11
US20110318834A1 (en) 2011-12-29
EP1762619A2 (de) 2007-03-14
EP0811061A1 (de) 1997-12-10
DE69636495D1 (de) 2006-10-12
JP2007082549A (ja) 2007-04-05
US6544784B1 (en) 2003-04-08
DE811061T1 (de) 2002-10-17
CA2213237A1 (en) 1996-08-22
EP1762619A3 (de) 2007-05-09
US20030190285A1 (en) 2003-10-09
EP0811061B1 (de) 2006-08-30
PL321831A1 (en) 1997-12-22
FI973354A7 (fi) 1997-10-16
KR19980702276A (ko) 1998-07-15
HUP9800028A3 (en) 2001-02-28
EP0727487A1 (de) 1996-08-21
WO1996025493A1 (en) 1996-08-22
EP0811061B2 (de) 2010-07-21

Similar Documents

Publication Publication Date Title
ATE338114T1 (de) Multi-tumor abweichende wachstumsgene
TR199501182A2 (tr) Pestisid özellikte yeni proteinler ve suslar.
ATE328896T1 (de) Faktor viii vom schwein und hybriden
ATE125867T1 (de) Fibronektinbindungsprotein und dessen herstellung.
CA2236166A1 (en) Enhancer-increased gene expression in plants
DE60021497D1 (de) Menschliche, für zyklische Nukleotide spezifische Phosphodiesterase
DK1208111T3 (da) Gener der koder for insekt-odorantreceptorer og anvendelser deraf
CY1106978T1 (el) Ενζυμα φωσφοδιεστερασης
NO974035L (no) En ny vekstfaktor og en genetisk sekvens som koder for denne
DK2256205T3 (da) Porphorymonas gingivalis-polypeptider og -polynukleotider
ATE387493T1 (de) Gene, die für proteine mit transglykolysierungsaktivität kodieren.
ATE120494T1 (de) Fibronectinbindungsprotein und dessen herstellung.
ATE493499T1 (de) Resistenz gegen schädlinge
FI961202A0 (fi) Grb3-3-geeni, sen variantteja ja niiden käyttöjä
DE69739346D1 (de) Gereinigtes sr-p70 protein
DE69934415D1 (de) Neuartiges collectin
ATE286123T1 (de) Klonierung von pheromon rezeptoren aus vertebraten und deren verwendungen
CO4480058A1 (es) Genes codificantes y procedimiento de expresion de una nueva enzima: ftalil amidasa
EE9900447A (et) Raudasiduvat valku ületootev taimerakk, taim või taimeosa, raudasiduvat valku kodeeriva nukleotiidjärjestuse kasutamine, nukleiinhape ja meetod põllukultuuride saamiseks
EA199900893A1 (ru) Бактериальные плазмиды
DK1129191T3 (da) Fremgangsmåder til diagnosticering eller behandling af neurologiske sygdomme
ES2187939T3 (es) Moleculas aisladas de acido nucleico codificantes de miembros de la familia ssx y utilizaciones de las mismas.
DE69838459D1 (de) Für den licht-überempfinlichkeitsphaenotyp kodierende nukleotidsequenzen von tomaten, dadurch kodierte proteine und deren verwendungen
DE69729780D1 (de) Protein mit Ethylendiamine-N,N'-Dibarnsteinsäure: Ethylendiamin Lyase Aktivität und dafür kodierendes Gen
BR0107799A (pt) Proteìna de interação de wt1 wtip

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties